Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comprehensive Clinical Evaluation of Weight-loss Drugs
ChiCTR2600122379Phase 4Not yet recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Apr 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of orlistat, liraglutide, beinaglutide, semaglutide, tirzepatide and 1 more in obesity and Overweight (6 arms), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoint: Percentage of weight reduction from baseline (weeks 4, 8, 12, 24) at week 24. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on ChiCTR2600122379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122379.